RxDoctor Payments DataLook up a doctor →

James Weisz, MD

Ophthalmology · New Haven, CTNPI 1639144967

Payments from drug & device makers

$14,381in general payments, 2019–2025

Across 203 payments — averaging $70.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • US Retina LLC$7K
  • Eyepoint US, Inc.$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Coherus Oncology, Inc.$937
  • Genentech USA, Inc.$718
  • Mallinckrodt Hospital Products Inc.$383
  • plus $2K from 14 others
$13,712in research payments, 2019–2025

Across 2 payments — averaging $6856.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eyepoint US, Inc.$14K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$14,381 in reported general payments places this provider in the 90th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$2,023,046
Medicare patients
508
Services billed
25,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →